| Literature DB >> 23810221 |
Johan Franck1, Nitya Jayaram-Lindström.
Abstract
The efficacy of medications for alcohol dependence remains modest, and there are no strong clinical predictors of treatment response. Approved medications include acamprosate (an N-methyl-d-aspartate receptor (NMDA) modulator), disulfiram (an acetaldehyde dehydrogenase inhibitor) and naltrexone (an opioid antagonist) while nalmefene (an opioid antagonist) is currently under review for approval in Europe. Clinical trials suggest that baclofen (a GABA-B agonist) and topiramate (an anticonvulsant) may be promising candidates, while several other drug candidates are currently evaluated at early clinical stages.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23810221 DOI: 10.1016/j.conb.2013.05.005
Source DB: PubMed Journal: Curr Opin Neurobiol ISSN: 0959-4388 Impact factor: 6.627